{"protocolSection":{"identificationModule":{"nctId":"NCT02100631","orgStudyIdInfo":{"id":"PXVX-VC-200-005"},"organization":{"fullName":"Bavarian Nordic","class":"INDUSTRY"},"briefTitle":"A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 O1 Serotype Inaba Strain CVD 103-HgR"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-05"},"primaryCompletionDateStruct":{"date":"2015-02","type":"ACTUAL"},"completionDateStruct":{"date":"2015-06","type":"ACTUAL"},"studyFirstSubmitDate":"2014-03-25","studyFirstSubmitQcDate":"2014-03-31","studyFirstPostDateStruct":{"date":"2014-04-01","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-07-02","resultsFirstSubmitQcDate":"2021-04-05","resultsFirstPostDateStruct":{"date":"2021-04-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-26","lastUpdatePostDateStruct":{"date":"2023-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bavarian Nordic","class":"INDUSTRY"},"collaborators":[{"name":"Emergent BioSolutions","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Demonstrate that the vaccine offers protection based on antibody levels in older adults and is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.","detailedDescription":"Demonstrate that seroconversion by classical Inaba vibriocidal antibody at Day 11 in older adults ages 46-64 years (inclusive) was non inferior to seroconversion at Day 11 in younger adults ages 18-45 years following vaccination with PXVX0200."},"conditionsModule":{"conditions":["Cholera"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":398,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"PXVX0200 in Older Adults","type":"EXPERIMENTAL","description":"PXVX0200 Single dose; liquid suspension after reconstitution with buffer; \\> 2x10\\^8 CFU in a liquid suspension","interventionNames":["Biological: PXVX0200"]},{"label":"Placebo in Older Adults","type":"PLACEBO_COMPARATOR","description":"Placebo physiological saline","interventionNames":["Biological: Placebo"]},{"label":"Historical Control: Adults Aged 18-45","type":"OTHER","description":"This arm consists of historical data from subjects who received a single dose of PXVX0200 in study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118","interventionNames":["Biological: PXVX0200"]}],"interventions":[{"type":"BIOLOGICAL","name":"PXVX0200","armGroupLabels":["Historical Control: Adults Aged 18-45","PXVX0200 in Older Adults"]},{"type":"BIOLOGICAL","name":"Placebo","armGroupLabels":["Placebo in Older Adults"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Seroconversion Rate at Day 11","description":"The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.","timeFrame":"Day 11"}],"secondaryOutcomes":[{"measure":"Geometric Mean Titer (GMT)","description":"The Day 11 vibriocidal GMTs were compared between older and younger adults.","timeFrame":"Day 11"}],"otherOutcomes":[{"measure":"Cumulative Seroconversion Through Day 29 Compared to Day 11 for Younger Adults","description":"The cumulative seroconversion through Day 29 for older adults was compared to the Day 11 seroconversion for the younger adults aged 18 - 45 yrs. Seroconversion is defined as a 4-fold rise in antibody titer relative to baseline values.","timeFrame":"Day 29"},{"measure":"Mean Fold Change in Vibriocidal Antibody Titer Between Day 1 and Day 11","description":"The mean log2 fold change between Day 1 and Day 11 in classical Inaba vibriocidal antibody titer attained by older adults was compared to the younger adults aged 18 - 45 yrs.","timeFrame":"Day 11"},{"measure":"Seroconversion Against Other V. Cholerae Biotypes/Serotypes","description":"Seroconversion of the vibriocidal antibody response against 4 V. cholerae biotypes/serotypes - classical Inaba, El Tor Inaba, classical Ogawa and El Tor Ogawa was assessed.","timeFrame":"Day 11"},{"measure":"Anti-CT Antibody Response in Older Adults","description":"The seroconversion of anti-Cholera Toxin (CT) antibody response in older adults was assessed.\n\nSeroconversion is defined as a 4-fold rise in anti-CT antibody titer relative to baseline values.","timeFrame":"Day 11"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Able to understand the study and give written consent.\n2. Healthy male and female adults, age 46-64 years (inclusive) without significant medical history, physical, or abnormal screening laboratory test results at screening.\n3. Women of childbearing potential must have had a negative urine pregnancy test at screening, prior to vaccination. Female subjects must be of non-childbearing potential (as defined as surgically sterile or postmenopausal for more than 1 year), or if of childbearing potential must be practicing abstinence or using an effective licensed method of birth control (eg, use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, intrauterine devices \\[IUDs\\], cervical sponges, diaphragms, condoms with spermicidal agents; or must have a vasectomized partner) within 2 months of vaccination and must agree to continue such precautions during the study.\n4. Willing and able to comply with the study requirements and procedures.\n\nExclusion Criteria:\n\n1. Currently active unstable or undiagnosed medical conditions including immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder requiring hospitalization, current drug or alcohol abuse. Examples of unstable or undiagnosed medical conditions including unstable angina pectoris, shortness of breath on exertion without clear etiology and chronic renal failure requiring dialysis. Examples of conditions that do not meet exclusion criteria include mild controlled hypertension, mild controlled asthma, and treated depression without hospitalization.\n2. Abnormal stool pattern defined as fewer than 3 stools per week or more than 2 stools per day in past 6 months.\n3. Regular use of laxatives in the past 6 months.\n4. Previously received a licensed or investigational cholera vaccine.\n5. History of cholera or enterotoxigenic E. coli infection (natural infection or experimental challenge).\n6. Travel to a cholera-endemic area in the previous 5 years.\n7. Received or plans to receive any other licensed vaccines, except for seasonal influenza vaccine, from 14 days prior to the study vaccination through to 29 days after vaccination.\n8. Received or plans to receive antibiotics or chloroquine within 14 days prior to the study vaccination through to 29 days after vaccination.\n9. Recipient of bone marrow or solid organ transplant.\n10. Use of systemic chemotherapy in the previous 5 years prior to the study.\n11. Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders diagnosed or treated during the past 5 years.\n12. Received or plans to receive systemic immunosuppressive therapy, radiation therapy, parenteral or high-dosage inhaled steroids (\\>800 µg/day of beclomethasone diproprionate or equivalent) within 6 months prior to the study vaccination through to Day 29.\n13. History of Guillain-Barré Syndrome.\n14. Pregnant or nursing.","healthyVolunteers":true,"sex":"ALL","minimumAge":"46 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"James McCarty, MD","affiliation":"Emergent Travel Health Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Coastal Clinical Research","city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Avail Clinical","city":"DeLand","state":"Florida","zip":"32720","country":"United States","geoPoint":{"lat":29.02832,"lon":-81.30312}},{"facility":"Miami Research Associates","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Palm Beach Research Center","city":"Palm Beach","state":"Florida","zip":"33409","country":"United States","geoPoint":{"lat":26.70562,"lon":-80.03643}},{"facility":"Emory University","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Johnson County Clin-Trials","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Heartland Research","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Central Kentucky Research","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"University of Kentucky","city":"Lexington","state":"Kentucky","zip":"40536","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Boston University","city":"Boston","state":"Massachusetts","zip":"02218","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Center for Pharmaceutical Research","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"St. Louis University","city":"St Louis","state":"Missouri","zip":"63104","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Coastal Carolina Research","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"Research Across America","city":"Dallas","state":"Texas","zip":"75234","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Jean Brown Research","city":"Salt Lake City","state":"Utah","zip":"84124","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"University of Vermont","city":"Burlington","state":"Vermont","zip":"05405","country":"United States","geoPoint":{"lat":44.47588,"lon":-73.21207}}]},"referencesModule":{"references":[{"pmid":"30772070","type":"RESULT","citation":"McCarty JM, Lock MD, Bennett S, Hunt KM, Simon JK, Gurwith M. Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial. Vaccine. 2019 Mar 7;37(11):1389-1397. doi: 10.1016/j.vaccine.2019.01.077. Epub 2019 Feb 13."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This study included healthy volunteers (46 - 64 years) who were not previously immunized against cholera. A total of 398 subjects randomized, of which 299 received study treatment and 99 received placebo. A total of 36 subjects from the treatment group continued in the Immune Sub-study population.\n\nThe historical control subjects are not included in the protocol enrollment number for PXVX-VC-200-005. They are solely a comparator population.","recruitmentDetails":"This study included healthy volunteers (46 - 64 years) who were not previously immunized against cholera. A total of 398 subjects randomized, of which 299 received study treatment and 99 received placebo. A total of 36 subjects from the treatment group continued in the Immune Sub-study population.","groups":[{"id":"FG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 Single dose; liquid suspension after reconstitution with buffer; \\> 1x10\\^9 CFU in a liquid suspension"},{"id":"FG001","title":"Placebo in Older Adults","description":"Placebo physiological saline"},{"id":"FG002","title":"Historical Control: Adults Aged 18-45","description":"This arm consists of historical data from subjects who received a single dose of PXVX0200 in study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"299"},{"groupId":"FG001","numSubjects":"99"},{"groupId":"FG002","numSubjects":"2688"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"292"},{"groupId":"FG001","numSubjects":"95"},{"groupId":"FG002","numSubjects":"2688"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"3 subjects randomized to treatment unable to receive vaccine as product not available,","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 is a live-attenuated cholera vaccine for single-dose oral administration. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."},{"id":"BG001","title":"Placebo in Older Adults","description":"The placebo consisted of 100 mL of physiological saline administered orally. Physiological saline was sourced by the clinical sites. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."},{"id":"BG002","title":"Historical Control: Adults Aged 18-45","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586, PubMed ID: 29317118"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"299"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"2688"},{"groupId":"BG003","value":"3086"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Between 46-64 years (inclusive)","categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"299"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"2688"},{"groupId":"BG003","value":"3086"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"53.8","spread":"4.99"},{"groupId":"BG001","value":"54.1","spread":"5.20"},{"groupId":"BG002","value":"30.0","spread":"7.8"},{"groupId":"BG003","value":"33.1","spread":"NA","comment":"Mean and standard deviation were not calculated for the total population as the historical control was not part of the original analysis of baseline characteristics. The historical control population is solely for comparison of immunogenicity variables in adults to older adults. Measures of dispersion of baseline characteristics across both populations is not applicable."}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"1482"},{"groupId":"BG003","value":"1698"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"135"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"1206"},{"groupId":"BG003","value":"1388"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"18"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"56"},{"groupId":"BG003","value":"58"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"9"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"671"},{"groupId":"BG003","value":"758"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"221"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"1855"},{"groupId":"BG003","value":"2153"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"52"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"38"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"299"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"2341"},{"groupId":"BG003","value":"2739"}]}]},{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"347"},{"groupId":"BG003","value":"347"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Seroconversion Rate at Day 11","description":"The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years.","populationDescription":"Immunogenicity Evaluable Population (IEP)","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"% of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 is a live-attenuated cholera vaccine for single-dose oral administration. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."},{"id":"OG001","title":"Historical Control: Adults Aged 18-45","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586, PubMed ID: 29317118"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"2687"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","lowerLimit":"86.4","upperLimit":"93.5"},{"groupId":"OG001","value":"93.5","lowerLimit":"92.5","upperLimit":"94.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The lower limit of the two sided 95% Wald CI on the difference in seroconversion rate was estimated by inverting a Z test with pooled variance. The lower limit of the CI had be greater than -10 percentage points to prove non-inferiority. The lower bound of the CI on the older adults serconversion rate was required to exceed 70%.","paramType":"Risk Difference (RD)","paramValue":"-3.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.7","ciUpperLimit":"0.4"}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT)","description":"The Day 11 vibriocidal GMTs were compared between older and younger adults.","populationDescription":"IEP","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Titer","timeFrame":"Day 11","groups":[{"id":"OG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 is a live-attenuated cholera vaccine for single-dose oral administration. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."},{"id":"OG001","title":"Historical Control: Adults Aged 18-45","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586, PubMed ID: 29317118"},{"id":"OG002","title":"Placebo in Older Adults","description":"Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"2688"},{"groupId":"OG002","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4282","lowerLimit":"3344","upperLimit":"5484"},{"groupId":"OG001","value":"9688","lowerLimit":"9067","upperLimit":"10351"},{"groupId":"OG002","value":"44","lowerLimit":"36","upperLimit":"56"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio (GMR)","paramValue":"0.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.34","ciUpperLimit":"0.57"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Seroconversion Through Day 29 Compared to Day 11 for Younger Adults","description":"The cumulative seroconversion through Day 29 for older adults was compared to the Day 11 seroconversion for the younger adults aged 18 - 45 yrs. Seroconversion is defined as a 4-fold rise in antibody titer relative to baseline values.","populationDescription":"IEP","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"% of participants","timeFrame":"Day 29","groups":[{"id":"OG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 is a live-attenuated cholera vaccine for single-dose oral administration. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."},{"id":"OG001","title":"Historical Control: Adults Aged 18-45","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586, PubMed ID: 29317118"},{"id":"OG002","title":"Placebo in Older Adults","description":"Placebo physiological saline"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"2687"},{"groupId":"OG002","value":"99"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","lowerLimit":"90.8","upperLimit":"96.6"},{"groupId":"OG001","value":"93.5","lowerLimit":"92.5","upperLimit":"94.4"},{"groupId":"OG002","value":"1.0","lowerLimit":"0.0","upperLimit":"5.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Analysis for information only. No non-inferiority margin specified.","paramType":"Risk Difference (RD)","paramValue":"0.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.2","ciUpperLimit":"3.5"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Fold Change in Vibriocidal Antibody Titer Between Day 1 and Day 11","description":"The mean log2 fold change between Day 1 and Day 11 in classical Inaba vibriocidal antibody titer attained by older adults was compared to the younger adults aged 18 - 45 yrs.","populationDescription":"IEP. Placebo was not included in this additional bridging analysis as increase in SVA titer from Day 1 to 11 is not applicable for placebo subjects.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold Change in Titer from Day 1","timeFrame":"Day 11","groups":[{"id":"OG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 is a live-attenuated cholera vaccine for single-dose oral administration. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."},{"id":"OG001","title":"Historical Control: Adults Aged 18-45","description":"This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586, PubMed ID: 29317118"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"2687"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","lowerLimit":"6.2","upperLimit":"7.0"},{"groupId":"OG001","value":"7.1","lowerLimit":"7.0","upperLimit":"7.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"Analysis for information only. No non-inferiority margin specified.","pValue":"0.0062","statisticalMethod":"t-test, 2 sided"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroconversion Against Other V. Cholerae Biotypes/Serotypes","description":"Seroconversion of the vibriocidal antibody response against 4 V. cholerae biotypes/serotypes - classical Inaba, El Tor Inaba, classical Ogawa and El Tor Ogawa was assessed.","populationDescription":"IEP. The Historical Control population is not included as testing against these other biotypes/serotypes was not included in that study.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"% of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 is a live-attenuated cholera vaccine for single-dose oral administration. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."},{"id":"OG001","title":"Placebo in Older Adults","description":"The placebo consisted of 100 mL of physiological saline administered orally. Physiological saline was sourced by the clinical sites. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"99"}]}],"classes":[{"title":"Classical Inaba","categories":[{"measurements":[{"groupId":"OG000","value":"90.4","lowerLimit":"86.4","upperLimit":"93.5"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"3.7"}]}]},{"title":"El Tor Inaba","categories":[{"measurements":[{"groupId":"OG000","value":"91.0","lowerLimit":"87.1","upperLimit":"94.1"},{"groupId":"OG001","value":"5.1","lowerLimit":"1.7","upperLimit":"11.4"}]}]},{"title":"Classical Ogawa","categories":[{"measurements":[{"groupId":"OG000","value":"73.2","lowerLimit":"67.7","upperLimit":"78.2"},{"groupId":"OG001","value":"2.0","lowerLimit":"0.2","upperLimit":"7.1"}]}]},{"title":"El Tor Ogawa","categories":[{"measurements":[{"groupId":"OG000","value":"71.4","lowerLimit":"65.8","upperLimit":"76.5"},{"groupId":"OG001","value":"6.1","lowerLimit":"2.3","upperLimit":"12.7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Anti-CT Antibody Response in Older Adults","description":"The seroconversion of anti-Cholera Toxin (CT) antibody response in older adults was assessed.\n\nSeroconversion is defined as a 4-fold rise in anti-CT antibody titer relative to baseline values.","populationDescription":"Immune Sub-Study Population. The Historical Control population is not included as anti-CT levels were not assessed in that study.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"% of participants","timeFrame":"Day 11","groups":[{"id":"OG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 is a live-attenuated cholera vaccine for single-dose oral administration. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."},{"id":"OG001","title":"Placebo in Older Adults","description":"The placebo consisted of 100 mL of physiological saline administered orally. Physiological saline was sourced by the clinical sites. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","lowerLimit":"38.1","upperLimit":"72.1"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"33.6"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Adverse event monitoring for this study will begin post-vaccination on Day 1 and will continue through Day 29 for all adverse events and the End-of-Study visit (Day 181) for serious adverse events. In order to fulfill safety reporting obligations, the Investigator should promptly report any SAEs resulting from study participation through the Day 181 visit.","description":"The Historical Control population is not included in this section as comparisons were not specified to be conducted in the protocol.\n\nAdverse events are reported for the safety population comprised of all randomized subjects who received either PXVX0200 or placebo.","eventGroups":[{"id":"EG000","title":"PXVX0200 in Older Adults","description":"PXVX0200 is a live-attenuated cholera vaccine for single-dose oral administration. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181.","deathsNumAffected":0,"deathsNumAtRisk":296,"seriousNumAffected":3,"seriousNumAtRisk":296,"otherNumAffected":37,"otherNumAtRisk":296},{"id":"EG001","title":"Placebo in Older Adults","description":"The placebo consisted of 100 mL of physiological saline administered orally. Physiological saline was sourced by the clinical sites. Subjects will be randomly assigned 3:1 to receive PXVX0200 (300) or placebo (100). Each subject will have at least 4 visits composed of a screening visit, a vaccination visit (Day 1), and post-vaccination visits at Day 11, and Day 29 telephone contacts will be made on Day 91 and 181.","deathsNumAffected":0,"deathsNumAtRisk":99,"seriousNumAffected":0,"seriousNumAtRisk":99,"otherNumAffected":11,"otherNumAtRisk":99}],"seriousEvents":[{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":296},{"groupId":"EG001","numAffected":0,"numAtRisk":99}]},{"term":"Spinal Compression Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":296},{"groupId":"EG001","numAffected":0,"numAtRisk":99}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":296},{"groupId":"EG001","numAffected":0,"numAtRisk":99}]}],"otherEvents":[{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":296},{"groupId":"EG001","numAffected":3,"numAtRisk":99}]},{"term":"Back Pain","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":296},{"groupId":"EG001","numAffected":2,"numAtRisk":99}]},{"term":"Decreased Appetite","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":296},{"groupId":"EG001","numAffected":0,"numAtRisk":99}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":296},{"groupId":"EG001","numAffected":2,"numAtRisk":99}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":296},{"groupId":"EG001","numAffected":2,"numAtRisk":99}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":296},{"groupId":"EG001","numAffected":1,"numAtRisk":99}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":296},{"groupId":"EG001","numAffected":1,"numAtRisk":99}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (15.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":296},{"groupId":"EG001","numAffected":0,"numAtRisk":99}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"David Cassie, Scientist, Clinical Research","organization":"Emergent BioSolutions Canada Inc.","email":"dcassie@ebsi.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Australia"]},"conditionBrowseModule":{"meshes":[{"id":"D002771","term":"Cholera"}],"ancestors":[{"id":"D014735","term":"Vibrio Infections"},{"id":"D016905","term":"Gram-Negative Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}